Matthew Beckerdite, MD
Family Medicine · Ofallon, MONPI 1821062266
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $219,388 of the $224,531 with a category attached, or 97.7%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 88.4% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $52,856, 2.3 times the $23,048 reported in 2019. Among family medicine clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 349 payments — averaging $643.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$198K
- Shire North American Group Inc$23K
- AbbVie$818
- Novo Nordisk$427
- Pfizer$416
- Amgen$294
- plus $1K from 23 others
What the payments were for
- Consulting fees$219,38898%
- Travel & lodging$1,9101%
- Food & beverage$3,2341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 141 | $198,417 |
| Shire North American Group Inc | 12 | $22,880 |
| AbbVie(2 entities) | 41 | $818 |
| Novo Nordisk | 25 | $427 |
| Pfizer | 44 | $416 |
| Amgen | 16 | $294 |
| Boehringer Ingelheim | 13 | $253 |
| GSK | 14 | $227 |
| Lilly USA, LLC | 9 | $174 |
| Axsome Therapeutics, Inc. | 1 | $115 |
| E.r. Squibb & Sons, L.L.C. | 5 | $89 |
| Merck | 4 | $65 |
| AstraZeneca | 3 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Arbor Pharmaceuticals, Inc. | 2 | $24 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Abbott | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Bayer | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$115
How this compares
$224,531 in reported general payments places this provider in the 95th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 73 | $91,759 |
| TrulicityDulaglutide | 52 | $76,169 |
| JardianceEmpagliflozin | 55 | $72,212 |
| EliquisApixaban | 67 | $65,918 |
| FarxigaDapagliflozin Propanediol | 30 | $30,696 |
| XareltoRivaroxaban | 21 | $25,937 |
| MounjaroTirzepatide | 24 | $25,057 |
| Repatha SureclickEvolocumab | 27 | $19,575 |
| JanuviaSitagliptin Phosphate | 16 | $14,803 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $12,944 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 53 | $12,579 |
| Praluent PenAlirocumab | 15 | $10,915 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $10,522 |
| Atorvastatin Calcium | 573 | $4,899 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,030 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $174 | $101,22676 claims |
| Novo NordiskOzempic | $427 | $91,75973 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $253 | $82,73475 claims |
| PfizerEliquis | $416 | $65,91867 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $46 | $46,67060 claims |
| Johnson & JohnsonXarelto | $13 | $25,93721 claims |
| MerckJanuvia | $65 | $14,80316 claims |
| GSKArexvy | $227 | $12,57953 claims |
| AbbVieSynthroid | $818 | $1,44527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Ofallon
- Stephen AdamsSpringfield$636K
- Justin PuckettKirksville$568K
- Roger CadySpringfield$175K
- James LasalleExcelsior Springs$130K
- Matthew TiefenbrunnSullivan$105K
- Ayobami OduwoleGrandview$92K
- Michael DonovanSaint Louis$78K
- Blair ThedingerKansas City$71K
- Christine MooreRaymore$57K
- Jon MattsonKansas City$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.